With the high expression of CEACAM6, L-DOS47 could be an ideal solution for treating cancers, such as lung, gastric, colorectal, and pancreatic cancers, in combination with chemo-, immuno-, and radiotherapies, as well as other therapeutic modalities, including cell and oncolytic viral therapies where acidosis is a limiting factor for efficacy [21,22]. This evidence concerns the gene CEACAM6 and pancreatic neoplasm.